Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Research & Development (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Research & Development for 4 consecutive years, with $40.9 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 33.77% to $40.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $148.1 million through Dec 2025, down 34.94% year-over-year, with the annual reading at $148.1 million for FY2025, 34.94% down from the prior year.
  • Research & Development for Q4 2025 was $40.9 million at Day One Biopharmaceuticals, up from $31.4 million in the prior quarter.
  • The five-year high for Research & Development was $92.1 million in Q2 2024, with the low at $15.0 million in Q1 2022.
  • Average Research & Development over 4 years is $37.0 million, with a median of $33.4 million recorded in 2023.
  • The sharpest move saw Research & Development skyrocketed 186.2% in 2024, then plummeted 60.75% in 2025.
  • Over 4 years, Research & Development stood at $26.0 million in 2022, then skyrocketed by 43.54% to $37.3 million in 2023, then surged by 65.53% to $61.8 million in 2024, then crashed by 33.77% to $40.9 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $40.9 million, $31.4 million, and $36.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.